Current State and Outlook for Digital Therapeutics in Europe

In this new downloadable brief, PRECISIONadvisors experts Katherine Leong and David Carr provide a quick overview of the current digital therapeutics landscape in Europe, taking a closer look at the rapidly-expanding list of interventions as well as the varied ways that EU countries are approaching policy, regulation and reimbursement.

LEARN MORE

Current State and Outlook for Digital Therapeutics in Europe2022-08-20T13:38:35-04:00

On Demand Webinar – A Novel Data and Analytics-Informed Approach to Launch Excellence

Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.

LEARN MORE

On Demand Webinar – A Novel Data and Analytics-Informed Approach to Launch Excellence2023-03-08T10:14:35-05:00

World EPA Congress 2022

Attending World EPA Congress March 22-24 in Amsterdam? Don’t miss PRECISIONadvisors Richard Macaulay and David Carr present “Gene Therapies Market Access: Lessons From The Past, Future Best Practice” March 23 at 11:45 CET, and be sure to stop by our booth to speak with one of our experts.

LEARN MORE

World EPA Congress 20222022-03-02T14:49:01-05:00

Virtual ISPOR Europe 2021

We’re excited to announce that the PRECISIONadvisors team will be presenting 2 podium presentations and 7 posters at Virtual ISPOR Europe 2021 30 November- 3 December.

LEARN MORE

Virtual ISPOR Europe 20212021-11-08T10:12:23-05:00

Webinar: Pricing Strategies for Advanced Therapies

There is no doubt that the advanced therapies sector is growing at an exponential rate. According to a recently published 2021 Report by ARM (Alliance for Regenerative Medicine), the sector has raised $14.1B in financing in the first half of 2021 which is already 71% of what was raised in all of 2020. In addition, there are over 2,600 advance therapy clinical trials being conducted with 264 of those trails being Phase 3 trials and another 1,500 being Phase 2 trials. 

LEARN MORE

Webinar: Pricing Strategies for Advanced Therapies2021-09-24T09:37:34-04:00

On-Demand Panel: CAR-TCR Summit, 2021

The promise of cell-based immunotherapy is giving hope to patients around the globe living with devastating disease; but the future of the cell therapy industry is still unclear. This panel discussion co-hosted by Precision for Medicine and Precision ADVANCE will feature key insights and discussion from advanced therapy leaders on the pros and cons of developing Autologous and Allogeneic cell therapies.

LEARN MORE

On-Demand Panel: CAR-TCR Summit, 20212021-10-21T12:52:00-04:00